https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5045 Sat 24 Mar 2018 07:45:38 AEDT ]]> A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18630 Mon 20 Jul 2015 16:38:11 AEST ]]>